Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R A Figlin

Showing results (11-20 of 89) with videos related to

Pageof 9
Sort By:
Seminars in Hematology|July 1, 1988
Anti-interferon antibodies: a perspectiveR A Figlin, L M Itri
Current Opinion in Oncology|March 1, 1993
Primary tumors of the lung other than lung cancerW C Pierce, R A Figlin
Seminars in Oncology Nursing|May 1, 1988
Tumor necrosis factor: current clinical status and implications for nursing managementN P Moldawer, R A Figlin
The New England Journal of Medicine|May 19, 1988
Intracranial recurrence of carcinoma after complete surgical resection of stage I, II, and III non-small-cell lung cancerR A Figlin, S Piantadosi, R Feld, et al.
The Cancer Journal From Scientific American|February 24, 2000
Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinomaA Belldegrun, O Shvarts, R A Figlin
Cancer Treatment Reports|May 1, 1983
Phase II trial of alpha (human leukocyte) interferon administered daily in adenocarcinoma of the colon/rectumR A Figlin, M Callaghan, G Sarna
American Journal of Hematology|December 10, 1999
Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemiaH Yang, M H Rosove, R A Figlin
Seminars in Oncology|February 1, 1995
Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinomaW C Pierce, A Belldegrun, R A Figlin
Seminars in Oncology|December 1, 1993
Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinomaR A Figlin, W C Pierce, A Belldegrun
Seminars in Urologic Oncology|November 1, 1996
Immunotherapy and gene therapyB J Gitlitz, A Belldegrun, R A Figlin
Pageof 9

Showing results (11-20 of 89) with videos related to

Sort By:
Pageof 9
Seminars in Hematology|July 1, 1988
Anti-interferon antibodies: a perspectiveR A Figlin, L M Itri
Current Opinion in Oncology|March 1, 1993
Primary tumors of the lung other than lung cancerW C Pierce, R A Figlin
Seminars in Oncology Nursing|May 1, 1988
Tumor necrosis factor: current clinical status and implications for nursing managementN P Moldawer, R A Figlin
The New England Journal of Medicine|May 19, 1988
Intracranial recurrence of carcinoma after complete surgical resection of stage I, II, and III non-small-cell lung cancerR A Figlin, S Piantadosi, R Feld, et al.
The Cancer Journal From Scientific American|February 24, 2000
Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinomaA Belldegrun, O Shvarts, R A Figlin
Cancer Treatment Reports|May 1, 1983
Phase II trial of alpha (human leukocyte) interferon administered daily in adenocarcinoma of the colon/rectumR A Figlin, M Callaghan, G Sarna
American Journal of Hematology|December 10, 1999
Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemiaH Yang, M H Rosove, R A Figlin
Seminars in Oncology|February 1, 1995
Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinomaW C Pierce, A Belldegrun, R A Figlin
Seminars in Oncology|December 1, 1993
Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinomaR A Figlin, W C Pierce, A Belldegrun
Seminars in Urologic Oncology|November 1, 1996
Immunotherapy and gene therapyB J Gitlitz, A Belldegrun, R A Figlin
Pageof 9